Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY

Next Previous
Search
Trial Profile

A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MuSicalE
  • Sponsors Roche

Most Recent Events

  • 13 Mar 2025 Planned End Date changed from 26 Jul 2025 to 25 Jan 2026.
  • 13 Mar 2025 Planned primary completion date changed from 26 Jul 2025 to 25 Jan 2026.
  • 28 Jun 2022 Results of 1-year follow-up data assessing (n=1720) the real-world effectiveness and safety of ocrelizumab for treating patients with multiple sclerosis, presented at the 8th Congress of the European Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top